STOCKHOLM, Sweden, May 6 /PRNewswire/ -- Swedish biotechnology firm
Bioption AB is partnering with the International AIDS Vaccine Initiative
(IAVI) to develop and test a new approach for vaccines that can train the
immune system to protect against HIV/AIDS. The vaccines are being built from a
proprietary technology, SFV alphavirus replicons, pioneered by scientists at
the Karolinska Institute, Sweden's premier biomedical research institute.
The nonprofit IAVI is financing and coordinating the research, with the
goal of starting human testing of SFV-based AIDS vaccines within two years.
Bioption and IAVI have agreed to use their joint ownership of any successful
AIDS vaccines to provide them to developing countries rapidly and at
The Bioption-IAVI team expands the roster of European countries partnering
with IAVI to accelerate the development and testing of AIDS vaccines.
Scientists and biotechnology companies in the UK, Germany and Switzerland are
collaborating with IAVI on other AIDS vaccines. The governments of the
Netherlands, UK, Ireland, Denmark and Norway provide financial support to
"The hunt for a safe and effective AIDS vaccine must be a global effort.
Europe in particular has a critical leadership role to play in helping end
this terrible epidemic," said Seth F. Berkley, MD, President and CEO of IAVI.
"We are confident that we can beat back HIV/AIDS with a preventive vaccine,
but not without first committing the world's best talent and resources to the
SFV: Early experiments suggest promise for AIDS vaccination
The Bioption-IAVI AIDS vaccines will be constructed from Semliki Forest
Virus (SFV) replicons. An SFV replicon is a genetically engineered version of
the naturally occurring alphavirus SFV, modified so it does not cause disease,
and further modified to include synthetic copies of a subset of HIV's genetic
material. The aim is for SFV replicons to deliver HIV genetic material to
human cells, in turn stimulating the immune system to develop defenses against
There is no risk of the SFV vaccines themselves causing AIDS, as they lack
critical components of HIV needed to assemble a functioning virus.
"In laboratory tests, SFV-based AIDS vaccines have shown great promise for
safely and effectively inducing anti-HIV immune responses," said Dr. Peter
Liljestrom, President and CEO of Bioption and Professor at the Karolinska
Institute. "Thus far, experimental SFV vaccines have prevented AIDS in
non-human primates. Our next step is to translate these encouraging signs into
vaccines for human testing." Bioption is also exploring the use of similar
technology for vaccines for other infectious diseases and cancer.
"The Bioption-IAVI team will be looking to see how SFV-based AIDS vaccines
stand up against others as far as conferring protection in a way that is
practical for developing countries," said Dr. Hans Wigzell, President of the
Karolinska Institute. "The ideal is a vaccine that is long-lasting after one
or just a few doses. In laboratory testing, SFV-based vaccines have engaged
the immune system at lower doses than other candidates."
Like other preventive AIDS vaccines now in development and testing, the
Bioption-IAVI vaccines will be intended for individuals uninfected with HIV,
to protect them if they are later exposed to the virus.
Accelerating progress through parallel testing of varied vaccine
Over the next few years, Bioption-IAVI SFV vaccines will be tested to
evaluate their individual safety and effectiveness -- as well as their promise
relative to other vaccines in the IAVI pipeline. IAVI's strategy is to speed
the search for a winning vaccine by pursuing a diverse portfolio of
possibilities, now numbering more than a half dozen candidates. IAVI hopes to
advance the most promising two or three of its vaccines to large-scale,
final-stage studies by 2007.
"Each of IAVI's vaccine candidates is a different answer to the question,
how do we most effectively package HIV genes into a vaccine to prevent AIDS?"
said Dr. Wayne Koff, IAVI's Senior Vice President for Research and
Development. "Right now, many technologies for an AIDS vaccine look promising
in the laboratory. We must fast-track them toward the ultimate arbiter of
success: human trials."
Specifically, the Bioption-IAVI SFV vaccines will be compared against a
DNA-based AIDS vaccine (now in human testing with IAVI support by the UK's
University of Oxford and Kenya's University of Nairobi) and a bacteria-based
candidate (being developed with IAVI sponsorship at the Institute of Human
Virology and expected to enter testing early next year by the Uganda Virus
Research Institute). Additionally, the SFV, DNA and bacterial vaccines will be
tried in combination with a fourth approach, MVA (also now in IAVI-sponsored
human testing by Oxford and Nairobi).
A state-of-the-art central laboratory at Imperial College of Science,
Technology and Medicine in London will coordinate IAVI's worldwide trials of
AIDS vaccines, ensuring that standardized equipment and criteria are used to
assess each candidate.
Human trials in partnership with developing countries
Human trials of the Bioption-IAVI SFV-based AIDS vaccines will likely take
place in India and potentially other countries in Asia as well as sub-Saharan
Africa. All IAVI-sponsored human vaccine trials are conducted by local
scientists in the countries hosting the studies, using protocols developed by
these researchers and approved by their governments.
Sites in Asia and Africa are slated for trials because the vaccines will
be constructed to closely match the strain of HIV, subtype C, common in these
HIV is an extremely variable virus, and it is unclear whether any vaccine
designed to work against one subtype of HIV will be effective against the
broad spectrum of subtypes circulating worldwide. With most other AIDS vaccine
projects focused on HIV subtype B, prevalent mostly in Europe and the US, IAVI
and its partners are developing and testing candidates for subtypes common in
areas of the developing world where the vast majority of new HIV infections
The International AIDS Vaccine Initiative (IAVI; http://www.iavi.org) is a
global nonprofit organization working to speed the search for preventive
vaccines to protect against HIV and AIDS and assure their global
accessibility. IAVI advocates worldwide for increased financial and political
commitment to AIDS vaccine science and access. IAVI invests to fast-track
promising experimental AIDS vaccines through product development and human
testing. Currently, more than a half dozen novel AIDS vaccines are in
development with IAVI support, and two are in human testing. IAVI is a
Collaborating Centre of the Joint United Nations Programme on HIV/AIDS
(UNAIDS), and its major funders include the Bill & Melinda Gates Foundation;
the Rockefeller, Sloan and Starr foundations; the World Bank; BD (Becton,
Dickinson & Co.); and the governments of the Netherlands, United Kingdom,
United States, Canada, Ireland, Denmark and Norway.
Bioption AB is a Swedish biotechnology company focusing on development of
vaccines against infectious disease and cancer. The central platform
technology is based on recombinant alphavirus molecules that can be delivered
both as non-replicating virus particles and as naked DNA.
SOURCE International AIDS Vaccine Initiative
Web Site: http://www.iavi.org